The Multiple Sclerosis Resource Centre
Saturday, 31 July 2010The MS 24 Hour Telephone Counselling Service 0800 783 0518 (then press 1)
MSRC Logo
Welcome viv
If you are not viv, please click here
 
Search this site
Information
Home
Site Map
About MS
MSRC Services
Get Involved
MS Research News
  New Discoveries
  Drugs
    Disease Modifying Drugs
    Low Dose Naltrexone - Latest News
    Sativex®
    Ampyra (Fampridine-SR)
    Gilenia® (FTY720)
    Movectro (Cladribine)
    Aimspro (Goats Serum)
      Aimspro Latest News
      Aimspro - Published Research Papers
      Aimspro - Oxford Optic Neuritis Trial
    Azathioprine
    Trimesta (Oral Estriol)
    Mitoxantrone and Copaxone Combination Therapy
    Laquinimod
    Teriflunomide
    MBP8298
    NeuroVax
    Tovaxin
    BHT-3009
    HiCy
    CHR-1103
    BG-12
    Zenapax (daclizumab)
    Rituximab (Rituxan)
    Cyclophosphamide
    Novantrone (Mitoxantrone)
    Campath
    MN-166 (Ibudilast)
    RPI-78M
    ATX-MS-1467
    RTL-1000
    Further Possible MS Drugs and Treatments
    Cannabis And Cannabinoid Research
    Minocycline
    Statins
    Modafinil
    Pycnogenol
    Viagra (sildenafil)
    Possible Drugs For The Treatment Of MS Symptoms
    Genetically Modified Drugs And Components
    Prokarin
    Esperanza Homeopathic NeuroPeptide
    PEGylated interferon beta-1a
  Endo-parasites & 'Helpful' Organisms
  MS Knowledge
  Paediatric Multiple Sclerosis Research
  Stem Cell Research & Treatment
  MS and Genetics Research
  Familial Risk of Multiple Sclerosis Research
  Environmental Factors And MS Research
  General Research News
  Quality Of Life Research
  Diet
  Vitamin D Research
  Cognition and Cognitive Issues Research
  Other Conditions Research
  Sex
  Alternative Therapies
  Exercise
  General Health
  Vaccinations & MS Research
  Bone Marrow Transplant Research
  Mercury Amalgam Fillings Research
  Vitamin B12 Research
  Optical Assessments and MS Diagnosis Research
  Botox Research
  Myelin Research
  Ethnic Groups and MS Research
  Neuropsychiatric and Psychological Research
  Pain Research
  Pregnancy And MS Research
  Hyperbaric Oxygen Therapy Research
  General Research Articles
  MS Meeting News
MSRC Groups
Useful Resources
The Best Bet Diet Group
Advertising
Current Vacancies At MSRC
MSRC Guest Book
 
Interactive
Join Us
Member Log In
My MSRC
Contact MSRC
Site Map
 

Investor in People
Investor in People

content management system by:
Content Management and Website architecture by datapartners.co.uk
You are here : Home : MS Research News : Drugs : Aimspro (Goats Serum) : Aimspro - Published Research Papers
Aimspro - Published Research Papers Print this page
 
Share |

Goat serum product 'Aimspro' restores conduction in demylienated human optic nerve fibres

Abstract

Acute optic neuritis is a common manifestation of multiple sclerosis. It presents as an episode of monocular blurring of central vision, with a pronounced effect on colour discrimination. While spontaneous resolution usually follows, successive attacks may result in irreversible and often, slowly progressive, visual loss. No medication has yet been available to improve visual function in these chronically affected patients. Here we present evidence of a promising approach to therapy along with electrophysiological indications of a remarkable rapidity of onset.

For the full paper from the Journal of Clinical Neuroscience click here

© Multiple Sclerosis Resource Centre



Related Items
Aimspro - Oxford Optic Neuritis Trial
Aimspro Latest News


Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.
© 2002 - 2010 MSRC  |  Registered Charity No 1033731  | FREEPHONE 0800 783 0518 |  Back to Top